EA201790213A1 - Молекулы, которые избирательно активируют регуляторные t-клетки, для лечения аутоиммунных заболеваний - Google Patents

Молекулы, которые избирательно активируют регуляторные t-клетки, для лечения аутоиммунных заболеваний

Info

Publication number
EA201790213A1
EA201790213A1 EA201790213A EA201790213A EA201790213A1 EA 201790213 A1 EA201790213 A1 EA 201790213A1 EA 201790213 A EA201790213 A EA 201790213A EA 201790213 A EA201790213 A EA 201790213A EA 201790213 A1 EA201790213 A1 EA 201790213A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cells
electorally
molecules
treatment
autoimmune diseases
Prior art date
Application number
EA201790213A
Other languages
English (en)
Other versions
EA038361B1 (ru
Inventor
Джеффри Грив
Original Assignee
Делиниа, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55163946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201790213(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Делиниа, Инк. filed Critical Делиниа, Инк.
Publication of EA201790213A1 publication Critical patent/EA201790213A1/ru
Publication of EA038361B1 publication Critical patent/EA038361B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Это изобретение относится к слитому белку между белком избирательного агониста IL-2αβγ (избирательный агонист IL-2) и белком Fc IgG. Фрагмент избирательного агониста IL-2 обеспечивает терапевтическую активность посредством избирательной активации IL-2αβγ формы рецептора, таким образом избирательно стимулируя регуляторные Т-клетки. Fc фрагмент обеспечивает пролонгированное время полужизни в циркуляции по сравнению с временем полужизни в циркуляции IL-2 или белка IL-2SA.
EA201790213A 2014-07-21 2015-07-20 Молекулы, которые избирательно активируют регуляторные t-клетки, для лечения аутоиммунных заболеваний EA038361B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461999241P 2014-07-21 2014-07-21
PCT/US2015/041177 WO2016014428A2 (en) 2014-07-21 2015-07-20 Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

Publications (2)

Publication Number Publication Date
EA201790213A1 true EA201790213A1 (ru) 2017-06-30
EA038361B1 EA038361B1 (ru) 2021-08-13

Family

ID=55163946

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202190903A EA202190903A3 (ru) 2014-07-21 2015-07-20 Молекулы, которые избирательно активируют регуляторные t-клетки, для лечения аутоиммунных заболеваний
EA201790213A EA038361B1 (ru) 2014-07-21 2015-07-20 Молекулы, которые избирательно активируют регуляторные t-клетки, для лечения аутоиммунных заболеваний

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA202190903A EA202190903A3 (ru) 2014-07-21 2015-07-20 Молекулы, которые избирательно активируют регуляторные t-клетки, для лечения аутоиммунных заболеваний

Country Status (22)

Country Link
US (6) US20170051029A1 (ru)
EP (2) EP3172227B9 (ru)
JP (2) JP6768633B2 (ru)
KR (1) KR102493543B1 (ru)
CN (2) CN106795213B (ru)
AU (3) AU2015292889C1 (ru)
CA (1) CA2954847A1 (ru)
DK (1) DK3172227T3 (ru)
EA (2) EA202190903A3 (ru)
ES (1) ES2763198T3 (ru)
GB (1) GB2538666A (ru)
HU (1) HUE046065T2 (ru)
IL (3) IL289475B2 (ru)
LT (1) LT3172227T (ru)
MX (2) MX2017000821A (ru)
PL (1) PL3172227T3 (ru)
PT (1) PT3172227T (ru)
RS (1) RS59789B1 (ru)
SG (2) SG10202010158TA (ru)
SI (1) SI3172227T1 (ru)
WO (1) WO2016014428A2 (ru)
ZA (1) ZA201700344B (ru)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109324190A (zh) 2012-12-11 2019-02-12 艾伯特叶史瓦大学爱因斯坦医学院 高通量受体:配体鉴定方法
SG10202010158TA (en) * 2014-07-21 2020-11-27 Delinia Inc Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
SG11201700629TA (en) 2014-08-11 2017-02-27 Delinia Inc Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
UA126270C2 (uk) 2015-04-10 2022-09-14 Емджен Інк. Мутеїни інтерлейкіну-2 для росту регуляторних t-клітин
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
KR20180133198A (ko) * 2016-05-04 2018-12-13 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
US11505591B2 (en) 2016-05-18 2022-11-22 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US11339201B2 (en) 2016-05-18 2022-05-24 Albert Einstein College Of Medicine Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
US11077172B2 (en) * 2016-11-08 2021-08-03 Delinia, Inc. IL-2 variants for the treatment of psoriasis
BR112019011799B1 (pt) 2016-12-13 2021-12-21 Delinia, Inc Proteína de fusão, proteína dimérica e composição farmacêutica
CN116970060A (zh) 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3596118A4 (en) 2017-03-15 2021-04-07 Cue Biopharma, Inc. PROCESSES FOR MODULATING AN IMMUNE RESPONSE
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
WO2018181638A1 (ja) * 2017-03-29 2018-10-04 国立大学法人宮崎大学 長時間作用型アドレノメデュリン誘導体
CA3064435A1 (en) 2017-05-24 2018-11-29 Pandion Therapeutics, Inc. Targeted immunotolerance
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
SG11202003965VA (en) * 2017-12-06 2020-06-29 Pandion Therapeutics Inc Il-2 muteins and uses thereof
JP2021506291A (ja) 2017-12-19 2021-02-22 ゼンコア インコーポレイテッド 改変されたｉｌ−２ ｆｃ融合タンパク質
WO2019131964A1 (ja) 2017-12-27 2019-07-04 協和発酵キリン株式会社 Ｉｌ－２改変体
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF
WO2019144309A1 (en) * 2018-01-24 2019-08-01 Beijing Percans Oncology Co. Ltd. Cytokine Fusion Proteins
EP3752178A1 (en) 2018-02-16 2020-12-23 Iltoo Pharma Use of interleukin 2 for treating sjögren's syndrome
MX2020009975A (es) 2018-03-28 2020-10-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso.
EP3552738A1 (en) * 2018-04-12 2019-10-16 Sandvik Machining Solutions AB A method of producing an additive manufactured object
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
KR20210055694A (ko) 2018-08-06 2021-05-17 메디카인 인코포레이티드 Il-2 수용체 결합 화합물
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
TW202034945A (zh) 2018-12-21 2020-10-01 大陸商江蘇恆瑞醫藥股份有限公司 一種人白細胞介素２變體或其衍生物
EP3917962A1 (en) 2019-02-01 2021-12-08 Regeneron Pharmaceuticals, Inc. Anti-il2 receptor gamma antigen-binding proteins
CN113661175A (zh) 2019-02-15 2021-11-16 整体分子公司 包含共同轻链的抗体及其用途
KR20210128443A (ko) 2019-02-15 2021-10-26 인테그럴 몰큘러 인코포레이티드 클라우딘 6 항체 및 이의 용도
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
CN114341189A (zh) 2019-06-12 2022-04-12 奥美药业有限公司 全新il-15前药及其应用
US20220306714A1 (en) * 2019-08-12 2022-09-29 AskGene Pharma, Inc. Il-2 fusion proteins that preferentially bind il-2ralpha
WO2021092081A1 (en) 2019-11-05 2021-05-14 Medikine, Inc. Dual il-2r and il-7r binding compounds
BR112022008744A2 (pt) 2019-11-05 2022-07-19 Medikine Inc Ligante de il-2rss, ligante de il-2r¿c, composto de ligação a il-2r¿¿c, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método de uma terapia celular, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico
JP2023505590A (ja) 2019-12-12 2023-02-09 イルトゥー・ファルマ インターロイキン２キメラ構築物
MX2022007754A (es) * 2019-12-20 2022-07-19 Regeneron Pharma Nuevos agonistas de il2 y metodos de uso de estos.
KR102653906B1 (ko) 2020-01-14 2024-04-03 신테카인, 인크. 편향된 il2 뮤테인 방법 및 조성물
MX2022009302A (es) 2020-02-03 2022-11-16 Medikine Inc Compuestos de unión a il-7r¿.
WO2021158623A1 (en) 2020-02-03 2021-08-12 Medikine, Inc. IL-7Rαγc BINDING COMPOUNDS
US11028132B1 (en) 2020-04-07 2021-06-08 Yitzhak Rosen Half-life optimized linker composition
MX2022013208A (es) 2020-05-12 2022-11-14 Cue Biopharma Inc Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos.
WO2021231773A1 (en) 2020-05-13 2021-11-18 Good Therapeutics, Inc. Compositions of protein complexes and methods of use thereof
KR20230097094A (ko) 2020-10-29 2023-06-30 브리스톨-마이어스 스큅 컴퍼니 질환의 치료를 위한 융합 단백질
JP2023549191A (ja) 2020-11-13 2023-11-22 江蘇恒瑞医薬股▲ふん▼有限公司 ヒトインターロイキン２の変異体又はその誘導体を含む医薬組成物及びその用途
EP4316528A1 (en) * 2021-03-31 2024-02-07 Hanmi Pharm. Co., Ltd. Novel immunoactive interleukin 2 analog conjugate and method for preparing same
CA3216364A1 (en) 2021-04-09 2022-10-13 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
WO2023057588A1 (en) 2021-10-06 2023-04-13 Iltoo Pharma Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023133319A1 (en) 2022-01-10 2023-07-13 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
WO2023172628A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
WO2023183568A1 (en) 2022-03-25 2023-09-28 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
US20230381277A1 (en) 2022-04-08 2023-11-30 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
WO2024056154A1 (en) 2022-09-12 2024-03-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukin-2 for use in treating autism spectrum disorder

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541610B1 (en) * 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
ATE375388T1 (de) 2001-07-27 2007-10-15 Us Gov Health & Human Serv Systeme zur stellengerichteten in-vivo-mutagenese mit oligonukleotiden
PT1454138E (pt) 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
SI1641823T1 (sl) 2003-06-12 2011-12-30 Lilly Co Eli Fuzijski proteini analogni glp-1
MXPA06000974A (es) * 2003-07-25 2006-08-31 Amgen Inc Antagonistas y agonistas de ldcam y metodos para su uso.
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
RU2006135112A (ru) * 2004-03-05 2008-04-10 Чирон Корпорейшн (Us) Тест-система in vitro для прогнозирования устойчивости пациента к терапевтическим средствам
EP2038417A2 (en) * 2006-07-06 2009-03-25 Merck Patent GmbH Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
SI2066694T1 (sl) * 2006-09-29 2016-02-29 Oncomed Pharmaceuticals, Inc. Sestavki in postopki za diagnosticiranje in zdravljenje raka
CA2749539C (en) * 2009-01-21 2022-07-19 Amgen Inc. Compositions and methods comprising interleukin-2 mutants for treating inflammatory and autoimmune diseases
ES2572728T3 (es) * 2009-03-20 2016-06-02 F. Hoffmann-La Roche Ag Anticuerpos anti-HER biespecíficos
IL300733A (en) * 2010-03-05 2023-04-01 Univ Johns Hopkins Compositions and methods for antibodies and fusion proteins targeting immune modulation
CN102174111B (zh) * 2011-01-25 2013-01-09 江苏省弗泰生物科技有限公司 人白介素2-Fc融合蛋白及其用途
DK3489255T3 (da) * 2011-02-10 2021-08-23 Roche Glycart Ag Muterede interleukin-2-polypeptider
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
JP2014094898A (ja) * 2012-11-07 2014-05-22 Univ Of Tsukuba 炎症性腸疾患に関連する、ＣＤ３００ａ発現細胞の活性調節剤を含有する医薬品、ならびにＣＤ３００ａ遺伝子欠損マウスおよびＣＤ３００ａ発現細胞の活性調節剤の使用
US9546203B2 (en) * 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
AU2014232416B2 (en) * 2013-03-15 2017-09-28 Xencor, Inc. Modulation of T Cells with Bispecific Antibodies and FC Fusions
CN103193887B (zh) * 2013-04-03 2015-02-04 江苏众红生物工程创药研究院有限公司 一种重组猪白细胞介素2-Fc融合蛋白及其编码基因和表达方法
SG10202010158TA (en) * 2014-07-21 2020-11-27 Delinia Inc Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

Also Published As

Publication number Publication date
EP3172227A2 (en) 2017-05-31
HUE046065T2 (hu) 2020-01-28
PL3172227T3 (pl) 2020-04-30
AU2015292889A1 (en) 2016-01-28
AU2020203480A1 (en) 2020-06-18
US20170327555A1 (en) 2017-11-16
EA202190903A3 (ru) 2021-12-31
IL250024A0 (en) 2017-03-30
ES2763198T3 (es) 2020-05-27
US20190375812A1 (en) 2019-12-12
GB201615553D0 (en) 2016-10-26
RS59789B1 (sr) 2020-02-28
US20220112260A1 (en) 2022-04-14
EP3172227B9 (en) 2020-01-08
AU2022204946A1 (en) 2022-07-28
MX2017000821A (es) 2017-08-18
WO2016014428A3 (en) 2016-03-24
LT3172227T (lt) 2020-02-10
ZA201700344B (en) 2020-08-26
PT3172227T (pt) 2019-12-06
AU2015292889C1 (en) 2023-01-19
IL289475B1 (en) 2023-06-01
IL250024B (en) 2020-11-30
KR20170028938A (ko) 2017-03-14
US20210047382A1 (en) 2021-02-18
SG11201700514SA (en) 2017-02-27
JP2021006038A (ja) 2021-01-21
IL289475A (en) 2022-02-01
EA202190903A2 (ru) 2021-07-30
US20170051029A1 (en) 2017-02-23
IL278299B (en) 2022-02-01
SI3172227T1 (sl) 2020-02-28
CN114133456A (zh) 2022-03-04
IL289475B2 (en) 2023-10-01
GB2538666A (en) 2016-11-23
AU2015292889B2 (en) 2020-02-27
JP2017527272A (ja) 2017-09-21
CN106795213B (zh) 2021-12-07
WO2016014428A2 (en) 2016-01-28
EP3587444A1 (en) 2020-01-01
MX2021000083A (es) 2021-03-25
EP3172227A4 (en) 2017-12-20
CN106795213A (zh) 2017-05-31
EA038361B1 (ru) 2021-08-13
US20170037102A1 (en) 2017-02-09
CA2954847A1 (en) 2016-01-28
SG10202010158TA (en) 2020-11-27
EP3172227B1 (en) 2019-09-04
JP6768633B2 (ja) 2020-10-14
DK3172227T3 (da) 2019-12-02
KR102493543B1 (ko) 2023-01-30

Similar Documents

Publication Publication Date Title
EA201790213A1 (ru) Молекулы, которые избирательно активируют регуляторные t-клетки, для лечения аутоиммунных заболеваний
EA201891656A1 (ru) Молекулы, которые избирательно активируют регуляторные t-клетки для лечения аутоиммунных заболеваний
EA201991142A1 (ru) Варианты il-2 для лечения аутоиммунных заболеваний
SV2017005548A (es) Proteinas de fusion
EA201791093A1 (ru) Антитела к cd47, способы и применение
GB2564823A (en) Compositions and methods for T-cell receptors reprogramming using fusion proteins
MX2020004206A (es) Variantes il-2 modificadas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunitarias.
UY36021A (es) Proteìnas fc multimèricas
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
NZ738008A (en) Tigit-binding agents and uses thereof
EA201891589A1 (ru) Условно активные гетеродимерные полипептиды и способы их применения
EA201791884A1 (ru) Химерные антигенные рецепторы против dll3 и способы применения
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
CL2016001968A1 (es) Proteinas de fusion de interleucina-2 y usos de las mismas
MX2017016502A (es) Anticuerpos contra cd40 con actividad agonista mejorada.
MX2016010953A (es) Proteinas de fc multimericas.
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
EA201790192A1 (ru) СПОСОБ СНИЖЕНИЯ Fc-РЕЦЕПТОРНОГО СВЯЗЫВАНИЯ МОЛЕКУЛ СЫВОРОТОЧНОГО IgG У СУБЪЕКТА
BR112016024515A2 (pt) proteínas do agonista do receptor trail de cadeia única
MX2018008339A (es) Multimeros fc de inmunoglobulina g recombinante.
PH12019501405A1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
EA201991005A1 (ru) Антитела и полипептиды, направленные против cd127
EA201791049A1 (ru) Комбинация анти-cs1 и анти-pd1 антител для лечения рака (миеломы)
BR112019011461A2 (pt) terapia celular à base de nk melhorada
EA201890035A1 (ru) Иммунотерапевтические режимы дозирования, включающие помалидомид и антитело к cs1 для лечения рака